HPV CD40HVac is under clinical development by LinKinVax Europe Spas and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 61% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HPV CD40HVac’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HPV CD40HVac overview
Vaccine is under development for the treatment of human papillomavirus (HPV) associated oropharyngeal cancer and head and neck cancer. It acts by targeting CD40 ligand and is being developed based on dendritic cell-targeting vaccine platform.
LinKinVax Europe Spas overview
LinKinVax Europe Spas is a biotechnology firm in the clinical stage. By utilising research undertaken at the Vaccination Research Institute, it is building a new protein-based vaccine platform that can speed up vaccine availability (VRI). The company is headquartered in France.
For a complete picture of HPV CD40HVac’s drug-specific PTSR and LoA scores, buy the report here.